Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Genetics and Genomics›3' Untranslated Regions
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

3' Untranslated Regions

Genetics and Genomics · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 3 min read

The sequence at the 3' end of messenger RNA that does not code for product.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (647 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

The sequence at the 3' end of messenger RNA that does not code for product. This region contains transcription and translation regulating sequences.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: 3' Untranslated Region; Region, 3' Untranslated; Regions, 3' Untranslated; Untranslated Region, 3'; Untranslated Regions, 3'; 3' UTR; 3' UTRs; UTR, 3'.

Where it fits in the MeSH classification

Broader topics
Untranslated Regions
Narrower topics
AU Rich Elements
See also
3' Flanking Region

Research landscape

PubMed indexes 17,048 records tagged with the MeSH heading “3' Untranslated Regions” (counts retrieved 2026-10-29). 3,061 of them (18.0%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 9,678 records.

Reviews account for 676 records (4.0%) and meta-analyses for 62. Randomized controlled trials number 22 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 249 records; 2000-2009: 4,060 records; 2010-2019: 9,678 records; 2020 onward: 3,061 records249through 19994,0602000-20099,6782010-20193,0612020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 1999249
2000-20094,060
2010-20199,678
2020 onward3,061
Share of records by publication typeReviews: 4.0 percent; Meta-analyses: 0.4 percent; Randomized controlled trials: 0.1 percentReviews4.0% (676)Meta-analyses0.4% (62)Randomized controlled trials0.1% (22)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 17,048 PubMed records
TypeRecordsShare
Reviews6764.0%
Meta-analyses620.4%
Randomized controlled trials220.1%

Method: PubMed query "3' Untranslated Regions"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in genetics and genomics

Genetic findings vary widely in strength. A variant linked to a condition in one study may not replicate in other ancestries, and most common variants have small effects that are meaningful only in aggregate. Studies of rare, high-impact variants can support strong causal claims about a gene, while association studies describe statistical links that need functional and independent replication. Check the sample size, the ancestry of participants, whether results were replicated, and whether a laboratory or clinical outcome was actually measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Cellular stress alters 3'UTR landscape through alternative polyadenylation and isoform-specific degradation
Zheng D, Wang R, Ding Q, Wang T, Xie B, Wei L, et al.
2018Research article
Design not recorded in structured metadata
128cc by
PMID 29891946 · DOI · PMC5995920
Transcriptome 3'end organization by PCF11 links alternative polyadenylation to formation and neuronal differentiation of neuroblastoma
Ogorodnikov A, Levin M, Tattikota S, Tokalov S, Hoque M, Scherzinger D, et al.
2018Research article
Design not recorded in structured metadata
99cc by
PMID 30552333 · DOI · PMC6294251
Mechanistic insights into mRNA 3'-end processing
Kumar A, Clerici M, Muckenfuss LM, Passmore LA, Jinek M
2019Review article
Design not recorded in structured metadata
94cc by
PMID 31499460 · DOI · PMC6900580
A 3'UTR-derived small RNA modulates the life cycle of the cholera toxin-encoding filamentous phage, CTXϕ
Lippegaus A, Haycocks JRJ, O'Driscoll E, Sprenger M, Thriene K, Jung EM, et al.
2026Research article
Design not recorded in structured metadata
3cc by
PMID 42228528 · DOI · PMC13250501

Cellular stress alters 3'UTR landscape through alternative polyadenylation and isoform-specific degradation [1]

Research article Zheng D, Wang R, Ding Q, Wang T, Xie B, Wei L, et al. · · 2018 · cited 128 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Most eukaryotic genes express alternative polyadenylation (APA) isoforms with different 3'UTR lengths, production of which is influenced by cellular conditions.
Closing excerpt
Together, our data reveal a global, 3'UTR-based mRNA stability control in stressed cells and indicate that APA can function as an adaptive mechanism to preserve mRNAs in response to stress.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (149 words)

Most eukaryotic genes express alternative polyadenylation (APA) isoforms with different 3'UTR lengths, production of which is influenced by cellular conditions. Here, we show that arsenic stress elicits global shortening of 3'UTRs through preferential usage of proximal polyadenylation sites during stress and enhanced degradation of long 3'UTR isoforms during recovery. We demonstrate that RNA-binding protein TIA1 preferentially interacts with alternative 3'UTR sequences through U-rich motifs, correlating with stress granule association and mRNA decay of long 3'UTR isoforms. By contrast, genes with shortened 3'UTRs due to stress-induced APA can evade mRNA clearance and maintain transcript abundance post stress. Furthermore, we show that stress causes distinct 3'UTR size changes in proliferating and differentiated cells, highlighting its context-specific impacts on the 3'UTR landscape. Together, our data reveal a global, 3'UTR-based mRNA stability control in stressed cells and indicate that APA can function as an adaptive mechanism to preserve mRNAs in response to stress.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29891946 · DOI · PMC5995920

Transcriptome 3'end organization by PCF11 links alternative polyadenylation to formation and neuronal differentiation of neuroblastoma [2]

Research article Ogorodnikov A, Levin M, Tattikota S, Tokalov S, Hoque M, Scherzinger D, et al. · · 2018 · cited 99 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Diversification at the transcriptome 3'end is an important and evolutionarily conserved layer of gene regulation associated with differentiation and dedifferentiation processes.
Closing excerpt
We provide an interactive data repository of transcriptome-wide APA covering > 170 RNAis, and an APA-network map with regulatory hubs.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (156 words)

Diversification at the transcriptome 3'end is an important and evolutionarily conserved layer of gene regulation associated with differentiation and dedifferentiation processes. Here, we identify extensive transcriptome 3'end-alterations in neuroblastoma, a tumour entity with a paucity of recurrent somatic mutations and an unusually high frequency of spontaneous regression. Utilising extensive RNAi-screening we reveal the landscape and drivers of transcriptome 3'end-diversification, discovering PCF11 as critical regulator, directing alternative polyadenylation (APA) of hundreds of transcripts including a differentiation RNA-operon. PCF11 shapes inputs converging on WNT-signalling, and governs cell cycle, proliferation, apoptosis and neurodifferentiation. Postnatal PCF11 down-regulation induces a neurodifferentiation program, and low-level PCF11 in neuroblastoma associates with favourable outcome and spontaneous tumour regression. Our findings document a critical role for APA in tumorigenesis and describe a novel mechanism for cell fate reprogramming in neuroblastoma with potentially important clinical implications. We provide an interactive data repository of transcriptome-wide APA covering > 170 RNAis, and an APA-network map with regulatory hubs.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30552333 · DOI · PMC6294251

Mechanistic insights into mRNA 3'-end processing [3]

Review article Kumar A, Clerici M, Muckenfuss LM, Passmore LA, Jinek M · · 2019 · cited 94 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The polyadenosine (poly(A)) tail found on the 3'-end of almost all eukaryotic mRNAs is important for mRNA stability and regulation of translation.
Closing excerpt
Here, we describe new molecular insights into pre-mRNA recognition, cleavage and polyadenylation.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (129 words)

The polyadenosine (poly(A)) tail found on the 3'-end of almost all eukaryotic mRNAs is important for mRNA stability and regulation of translation. mRNA 3'-end processing occurs co-transcriptionally and involves more than 20 proteins to specifically recognize the polyadenylation site, cleave the pre-mRNA, add a poly(A) tail, and trigger transcription termination. The polyadenylation site (PAS) defines the end of the 3'-untranslated region (3'-UTR) and, therefore, selection of the cleavage site is a critical event in regulating gene expression. Integrated structural biology approaches including biochemical reconstitution of multi-subunit complexes, cross-linking mass spectrometry, and structural analyses by X- ray crystallography and single-particle electron cryo-microscopy (cryoEM) have enabled recent progress in understanding the molecular mechanisms of the mRNA 3'-end processing machinery. Here, we describe new molecular insights into pre-mRNA recognition, cleavage and polyadenylation.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31499460 · DOI · PMC6900580

A 3'UTR-derived small RNA modulates the life cycle of the cholera toxin-encoding filamentous phage, CTXϕ [4]

Research article Lippegaus A, Haycocks JRJ, O'Driscoll E, Sprenger M, Thriene K, Jung EM, et al. · · 2026 · cited 3 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Bacteriophages (phages) are well known to be one of the major driving forces in bacterial evolution.
Closing excerpt
cholerae employs sRNA-mediated posttranscriptional gene regulation to coordinate CTXϕ activation with both cell density and nutrient availability.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (213 words)

Bacteriophages (phages) are well known to be one of the major driving forces in bacterial evolution. This also applies to virulent microorganisms, such as the major human pathogen Vibrio cholerae, whose pathogenic potential and epidemic proliferation largely depends on the interaction with environmental phages. Specifically, integration of the CTXϕ phage genome into the first chromosome of V. cholerae also introduced the ctxAB genes, encoding the primary toxin responsible for the severe acute diarrheal disease, cholera. Whereas the mechanisms underlying CTXϕ-associated horizontal gene transfer and transcriptional control of the ctxAB genes have been intensively studied over the past years, posttranscriptional regulation affecting the CTXϕ life cycle has not been documented. Here, we report the identification and characterization of the CisR small RNA (sRNA) that is produced from the 3'UTR (untranslated region) of the prtV gene and inhibits the expression of the CTXϕ-encoded cep mRNA. CisR-mediated repression of cep involves Hfq-assisted base-pairing of the two transcripts and results in reduced CTXϕ production under stress conditions. We further demonstrate that transcription of prtV-cisR requires both the master quorum-sensing regulator HapR and CRP (cAMP receptor protein), a global regulator of carbon metabolism. Taken together, our work provides evidence that V. cholerae employs sRNA-mediated posttranscriptional gene regulation to coordinate CTXϕ activation with both cell density and nutrient availability.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42228528 · DOI · PMC13250501

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Alternative polyadenylation of mRNA precursors [5]
    Tian B, Manley JL · Nat Rev Mol Cell Biol · 2017 · cited 1,080 times (Europe PMC)
  • Research article AU-rich elements and associated factors: are there unifying principles? [6]
    Barreau C, Paillard L, Osborne HB · Nucleic Acids Res · 2005 · cited 828 times (Europe PMC)
  • Research article A PUF family portrait: 3'UTR regulation as a way of life [7]
    Wickens M, Bernstein DS, Kimble J, Parker R · Trends Genet · 2002 · cited 526 times (Europe PMC)
  • Research article Regulation by 3'-Untranslated Regions [8]
    Mayr C · Annu Rev Genet · 2017 · cited 518 times (Europe PMC)
  • Research article What Are 3' UTRs Doing? [9]
    Mayr C · Cold Spring Harb Perspect Biol · 2019 · cited 451 times (Europe PMC)
  • Research article The power of the 3' UTR: translational control and development [10]
    Kuersten S, Goodwin EB · Nat Rev Genet · 2003 · cited 416 times (Europe PMC)

References

  1. Zheng D, Wang R, Ding Q, Wang T, Xie B, Wei L, et al.. Cellular stress alters 3'UTR landscape through alternative polyadenylation and isoform-specific degradation. . 2018. PMID 29891946 · DOI · PMC5995920
  2. Ogorodnikov A, Levin M, Tattikota S, Tokalov S, Hoque M, Scherzinger D, et al.. Transcriptome 3'end organization by PCF11 links alternative polyadenylation to formation and neuronal differentiation of neuroblastoma. . 2018. PMID 30552333 · DOI · PMC6294251
  3. Kumar A, Clerici M, Muckenfuss LM, Passmore LA, Jinek M. Mechanistic insights into mRNA 3'-end processing. . 2019. PMID 31499460 · DOI · PMC6900580
  4. Lippegaus A, Haycocks JRJ, O'Driscoll E, Sprenger M, Thriene K, Jung EM, et al.. A 3'UTR-derived small RNA modulates the life cycle of the cholera toxin-encoding filamentous phage, CTXϕ. . 2026. PMID 42228528 · DOI · PMC13250501
  5. Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. Nat Rev Mol Cell Biol. 2017. PMID 27677860 · DOI · PMC5483950
  6. Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res. 2005. PMID 16391004 · DOI · PMC1325018
  7. Wickens M, Bernstein DS, Kimble J, Parker R. A PUF family portrait: 3'UTR regulation as a way of life. Trends Genet. 2002. PMID 11858839 · DOI
  8. Mayr C. Regulation by 3'-Untranslated Regions. Annu Rev Genet. 2017. PMID 28853924 · DOI
  9. Mayr C. What Are 3' UTRs Doing?. Cold Spring Harb Perspect Biol. 2019. PMID 30181377 · DOI · PMC6771366
  10. Kuersten S, Goodwin EB. The power of the 3' UTR: translational control and development. Nat Rev Genet. 2003. PMID 12897774 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Untranslated RegionsGenetics and Genomics
  • CodonGenetics and Genomics
  • OperonGenetics and Genomics
  • AllelesGenetics and Genomics
  • AnticodonGenetics and Genomics
  • EpigenomeGenetics and Genomics

All 95 articles in Genetics and Genomics →

At a glance

17,048
PubMed records on this heading
18%
published since 2020
676
review articles
22
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Untranslated RegionsGenetics and Genomics
  • CodonGenetics and Genomics
  • OperonGenetics and Genomics
  • AllelesGenetics and Genomics
  • AnticodonGenetics and Genomics

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support